

1 **Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates**  
2 **from the United Kingdom**

3 T P H Ngo<sup>1</sup>, P Smith<sup>2</sup>, K L Bartie<sup>1</sup>, K D Thompson<sup>3</sup>, D W Verner-Jeffreys<sup>4</sup>, R Hoare<sup>1</sup>, A  
4 Adams<sup>1</sup>

5 <sup>1</sup> Institute of Aquaculture, University of Stirling, Stirling, UK

6 <sup>2</sup> National University of Ireland, Galway, Ireland

7 <sup>3</sup> Moredun Research Institute, Pentlands Science Park, Penicuik, UK

8 <sup>4</sup> The Centre for Environment, Fisheries and Aquaculture Science, The Nothe,  
9 Weymouth, UK

10

11 **Correspondence:** *T P H Ngo, Institute of Aquaculture, University of Stirling, Stirling*

12 *FK9 4LA (e-mail: [nhpthao.snn@tphcm.gov.vn](mailto:nhpthao.snn@tphcm.gov.vn))*

13

14 This is the peer reviewed version of the following article: Ngo TPH, Smith P, Bartie KL, et al.  
15 Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates from the United Kingdom.  
*Journal of Fish Diseases* 2018;41:309–320, which has been published in final form at  
<https://doi.org/10.1111/jfd.12730>. This article may be used for non-commercial purposes in  
accordance With Wiley Terms and Conditions for self-archiving.

16 **Abstract**

17 Routine application of antimicrobials is the current treatment of choice for rainbow trout  
18 fry syndrome (RTFS) or bacterial coldwater disease (BCWD) caused by *Flavobacterium*  
19 *psychrophilum*. In this study, the antimicrobial susceptibilities of 133 *F. psychrophilum*  
20 isolates, 118 of which were from the UK, were evaluated by broth microdilution and disc  
21 diffusion methods following VET04-A2 and VET03-A guidelines of Clinical and  
22 Laboratory Standards Institute (CLSI), respectively. Isolates were categorised as wild  
23 type (fully susceptible, WT) or non-wild type (NWT) using normalised resistance  
24 interpretation (NRI) determined cut-off values ( $CO_{WT}$ ). Broth microdilution testing  
25 showed that only 12% of UK isolates were WT to oxolinic acid ( $MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$ )  
26 and 42% were WT for oxytetracycline ( $MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$ ). In contrast, all the  
27 isolates tested were WT ( $MIC\ CO_{WT} \leq 2\text{ mg L}^{-1}$ ) for florfenicol, the main antimicrobial  
28 for RTFS control in the UK. Disc diffusion-based  $CO_{WT}$  values were  $\geq 51\text{ mm}$  for 10  $\mu\text{g}$   
29 amoxicillin,  $\geq 44\text{ mm}$  for 30  $\mu\text{g}$  florfenicol,  $\geq 30\text{ mm}$  for 2  $\mu\text{g}$  oxolinic acid and  $\geq 51\text{ mm}$   
30 for 30  $\mu\text{g}$  oxytetracycline. There was a high categorical agreement between the  
31 classifications of the isolates by two testing methods for florfenicol (100%),  
32 oxytetracycline (93%), and oxolinic acid (99%).

33

34 *Keywords:* *Flavobacterium psychrophilum*, antimicrobial susceptibility, epidemiological  
35 cut-off values, disc diffusion, broth microdilution, rainbow trout fry syndrome.

## 36 **Introduction**

37 *Flavobacterium psychrophilum*, a Gram-negative, filamentous, psychrotrophic bacterium,  
38 is the aetiological agent of rainbow trout fry syndrome (RTFS) and bacterial coldwater  
39 disease (BCWD), which was first described in USA in 1946 (Borg 1948). *F.*  
40 *psychrophilum* infection has been found throughout North America, Europe and  
41 elsewhere in Turkey, Australia, Peru, Japan and Korea (Barnes & Brown 2011). A  
42 commercial vaccine against RTFS/BCWD is still not available (Gómez *et al.* 2014).  
43 Although phage therapy (Stenholm *et al.* 2008; Kim *et al.* 2010a; Castillo *et al.* 2012) and  
44 the use of probiotic bacteria (StrömBesto & Wiklund 2011; Korkea-aho *et al.* 2011;  
45 Boutin *et al.* 2012; Burbank *et al.* 2012) have been suggested to be a promising  
46 alternative to the use of antibiotics in aquaculture, further studies are needed to prove the  
47 consistent effect of these green/blue technologies on preventing the infection of *F.*  
48 *psychrophilum*. Therefore, the use of antibiotics is currently the treatment of choice for  
49 controlling RTFS/BCWD outbreaks, resulting in a concern about the development of  
50 antimicrobial resistance by *F. psychrophilum* (Gómez *et al.* 2014). In the UK, three  
51 antibiotics (florfenicol, oxytetracycline and amoxicillin) are licensed for use in  
52 aquaculture by the UK Veterinary Medicines Directorate (VMD)  
53 (<http://www.vmd.defra.gov.uk/>).

54 Several studies have examined the antimicrobial susceptibility of *F. psychrophilum*  
55 isolated from the USA (Pacha 1968, Soule *et al.* 2005; Van Vliet *et al.* 2017), the UK  
56 (Rangdale *et al.* 1997; Verner-Jeffreys & Taylor 2015; Smith *et al.* 2016), Denmark  
57 (Lorenzen *et al.* 1997; Bruun *et al.* 2000; Dalsgaard & Madsen 2000; Schmidt *et al.*

58 2000; Bruun *et al.* 2003; Smith *et al.* 2016), France (Michel *et al.* 2003), Japan (Izumi &  
59 Aranishi 2004), Turkey (Kum *et al.* 2008; Durmaz *et al.* 2012; Boyacioğlu & Akar 2012;  
60 Boyacioğlu *et al.* 2015), Canada (Hesami *et al.* 2010), Spain (Del Cerro *et al.* 2010),  
61 Norway (Nilsen *et al.* 2011), Chile (Henríquez-Núñez *et al.* 2012; Miranda *et al.* 2016)  
62 and Finland (Sundell *et al.* 2013). However, differences in the medium and growth  
63 conditions used in these studies and variations in the interpretive criteria used make  
64 comparisons difficult. In addition, some of these studies included only a small number of  
65 isolates, while others produced susceptibility data that was too diverse to allow any  
66 estimate of cut-off values to interpret their meaning.

67 Smith *et al.* (2013) addressed the need for standardised and internationally  
68 recognized protocols for laboratory *in vitro* susceptibility testing in monitoring and  
69 surveillance programmes and the use of standardised methods to calculate  
70 epidemiological cut-off values for interpretation of the meaning of the data collected in  
71 such surveys.

72 The aim of the present study was to evaluate the antimicrobial susceptibility of 140  
73 *F. psychrophilum* isolates, 125 of which were obtained within the UK, by the disc  
74 diffusion and standardised broth microdilution methods following VET03-A (CLSI 2006)  
75 and VET04-A2 (CLSI 2014a) guidelines respectively, as recommended by the Clinical  
76 and Laboratory Standards Institute (CLSI) for aquatic bacteria with an optimal growth  
77 temperature below 35°C.

78

## 79 **Materials and Methods**

## 80 **Bacterial isolates and growth conditions**

81 A total of 140 *F. psychrophilum* isolates, previously described by Ngo *et al.* (2017) for  
82 genetic and serological diversity, were examined in this study. This collection comprised  
83 125 isolates obtained within the UK during 2005-2015 and 15 isolates from other  
84 countries (France, Denmark, Finland, Ireland, Chile and the USA) (Table 1 and 2); 123  
85 *F. psychrophilum* isolates were obtained from rainbow trout (*Oncorhynchus mykiss*), 16  
86 from Atlantic salmon (*Salmo salar*) and one from coho salmon (*O. kisutch*). *F.*  
87 *psychrophilum* type strain NCIMB 1947<sup>T</sup> (ATCC 49418<sup>T</sup>) was included for comparative  
88 purposes. For all the experiments, the *F. psychrophilum* isolates were grown in Modified  
89 Veggietone (MV) medium [veggitones GMO-free soya peptone (Oxoid, UK), 5 g L<sup>-1</sup>;  
90 yeast extract (Oxoid, UK), 0.5 g L<sup>-1</sup>; magnesium sulphate heptahydrate (Fisher chemicals,  
91 UK), 0.5 g L<sup>-1</sup>; anhydrous calcium chloride (BHD), 0.2 g L<sup>-1</sup>; dextrose (Oxoid, UK), 2 g  
92 L<sup>-1</sup>; agar (solid medium; Oxoid, UK), 15 g L<sup>-1</sup>; pH 7.3] at 18°C for 72 – 96 h. Broth  
93 cultures were shaken at 140 rpm. Stock cultures were maintained at -70°C in tryptone–  
94 yeast extract–salts medium supplemented with glucose [FLP – tryptone (Oxoid, UK), 4.0  
95 g L<sup>-1</sup>; yeast extract, 0.4 g L<sup>-1</sup>; anhydrous calcium chloride, 0.2 g L<sup>-1</sup>; magnesium sulphate  
96 heptahydrate, 0.5 g L<sup>-1</sup>; D(+)-glucose (Sigma, UK), 0.5 g L<sup>-1</sup>; Cepeda *et al.* 2004] with  
97 10% glycerol and on Protect-Multi-purpose cryobeads (Technical Service Consultants  
98 Ltd, UK).

99         The 125 isolates from 27 sites within the UK in this study had been isolated  
100 between 2005 and 2015 with the majority (110 strains, 88%) being retrieved between  
101 2011 and 2013. Among these isolates, 51 genotypes and 7 plasmid profiles were detected

102 (Ngo *et al.* 2017) (Table 1). However, within this set of 125 isolates, there were five  
103 groups of two or three isolates that were recorded as having the same site, sampling time  
104 point, genetic profiles and susceptibilities. In order to avoid the over-representation, 7  
105 potential replicates were eliminated from the analysis and only 118 UK isolates were  
106 included in the analyses. The epidemiological cut-off values were calculated from the  
107 data obtained from 118 UK isolates and 15 isolates from other countries. The frequencies  
108 of NWT phenotypes circulating the UK during 2005 – 2015 were estimated from the  
109 analysis of 118 isolates.

110

#### 111 **Minimum inhibitory concentration (MIC) testing**

112 The MICs for *F. psychrophilum* isolates were performed using Sensititre CMP1MSP  
113 plates (Trek Diagnostic Systems; ThermoScientific.com/microbiology). These test plates  
114 were 96-well, dry-form plates that contained twofold serial dilutions of the following  
115 antimicrobial agents: ampicillin (AMP) 0.03–16 mg L<sup>-1</sup>, amoxicillin (AMOX) 0.25–16  
116 mg L<sup>-1</sup>, erythromycin (ERY) 0.25–128 mg L<sup>-1</sup>, enrofloxacin (ENRO) 0.002–1 mg L<sup>-1</sup>,  
117 florfenicol (FFN) 0.03–16 mg L<sup>-1</sup>, flumequine (FLUQ) 0.008–4 mg L<sup>-1</sup>,  
118 ormetoprim/sulphadimethoxine (PRI) 0.008/0.15–4/76 mg L<sup>-1</sup>, oxolinic acid (OXO)  
119 0.004–2 mg L<sup>-1</sup>, oxytetracycline (OTC) 0.015–8 mg L<sup>-1</sup> and  
120 trimethoprim/sulphamethoxazole (SXT) 0.015/0.3–1/19 mg L<sup>-1</sup>.

121 The MIC assays were determined using the broth microdilution protocol  
122 recommended for *F. psychrophilum* in the CLSI guideline VET04-A2 (CLSI 2014a).

123 Colony counts on inoculum suspensions were performed to ensure that the final inoculum  
124 density was close to  $5.0 \times 10^5$  colony-forming units (CFU) per millilitre.

125

### 126 **Disc diffusion testing**

127 Disc diffusion susceptibility of the *F. psychrophilum* strains was determined by the  
128 protocol suggested in the guideline VET03-A (CLSI 2006) with modification on the agar  
129 percentage of the culture medium. It should be noted, however, that this protocol has not  
130 been formally accepted as a standard by CLSI. The test was performed on diluted  
131 Mueller-Hinton medium (Sigma-Aldrich, UK;  $3 \text{ g L}^{-1}$ ) containing 1.5% agar (Agar No.  
132 1, LP0011, Oxoid, UK) (MHA) and 5% foetal calf serum (FCS; Gibco, Fisher  
133 chemicals, UK) and plates were incubated at  $15^\circ\text{C}$  for 68 – 72 h. Antimicrobial agent  
134 discs (Oxoid, Basingstoke, UK) containing 10  $\mu\text{g}$  amoxicillin (AMOX<sub>10</sub>), 5  $\mu\text{g}$   
135 enrofloxacin (ENRO<sub>5</sub>), 30  $\mu\text{g}$  florfenicol (FFN<sub>30</sub>), 2  $\mu\text{g}$  oxolinic acid (OXO<sub>2</sub>), 30  $\mu\text{g}$   
136 oxytetracycline (OTC<sub>30</sub>) and 25  $\mu\text{g}$  trimethoprim/sulphamethoxazole (SXT<sub>25</sub>) were  
137 employed.

138

### 139 **Quality control**

140 As specified in VET04-A2 (CLSI 2014a) the quality control strain *Escherichia coli*  
141 NCIMB 12210 (ATCC<sup>®</sup> 25922) was included in every MIC test run and was assayed on  
142 diluted CAMHB at  $18^\circ\text{C}$  as described above. However, no quality control ranges have  
143 been established for any disc diffusion protocol specifying these incubation conditions

144 (CLSI 2006). Therefore, the *F. psychrophilum* type strain NCIMB 1947<sup>T</sup> was also  
145 included in every test run to monitor the performance of the method.

146

### 147 **Statistical analysis**

148 The antimicrobial susceptibility patterns of 133 *F. psychrophilum* isolates used in this  
149 study were analysed by application of protocol and species-specific epidemiological cut-  
150 off values (CO<sub>WT</sub>). These values allow isolates to be categorised as fully susceptible  
151 (wild type, WT) or manifesting reduced susceptibility (non-wild type, NWT). In this  
152 work, CO<sub>WT</sub> values were calculated for both the MIC and disc diffusion data by the  
153 normalised resistance interpretation (NRI) method (Kronvall 2003; 2010). This NRI  
154 method was used with permission from the patent holder, Bioscand AB, TÄY, Sweden  
155 (European patent No 1383913, US patent No 7,465,559).

156 MIC distributions were analysed using the NRI method of Kronvall (2010). A fully  
157 automatic Excel spreadsheet for performing these NRI analyses is available on-line  
158 (<http://www.bioscand.se/nri/>). In data sets where a small percentage (<5 %) of the WT  
159 observations were “below-scale”, these observations were treated as having the MIC  
160 value immediately below the limit of the plate quantitation. When the percentage of the  
161 WT observations “below-scale” was >5%, the data set was considered as unsuitable for  
162 NRI analysis (Smith *et al.* 2016).

163 The NRI analyses for zone histograms were performed using a modification of the  
164 standardised protocol developed by Kronvall & Smith (2016). In this modification, the

165 peak values of the zone sizes for the putative WT isolates were established using 8-point  
166 rather than 4-point rolling means.

167

## 168 **Terminology**

169 The acronyms ECV and ECOFF have been used by the CLSI and European Committee  
170 on antimicrobial susceptibility testing (EUCAST) respectively for epidemiological cut-  
171 off values set from data generated in multiple laboratories. In the present study, the term  
172 CO<sub>WT</sub>, as previously employed by Smith *et al.* (2016), was used to indicate  
173 epidemiological cut-off values that have not been set by either of these international  
174 agencies. It has been suggested that the terms resistant and sensitive should not be used to  
175 refer to the categories identified by epidemiological cut-off values (Silley 2012).  
176 Following this suggestion, when isolates are categorised by epidemiological cut-off  
177 values, the terms wild type (WT) and non-wild type (NWT) should be used for fully  
178 susceptible isolates and isolates exhibiting reduced susceptibility respectively.

179

## 180 **Results**

### 181 **Quality control**

182 The MIC values obtained with the quality control reference strain *E. coli* NCIMB 12210,  
183 grown at 18°C for 72-96 h in diluted CAMHB, were within the acceptable range  
184 published by CLSI in VET03/04-S2 guideline (CLSI 2014b). All the inoculum  
185 suspensions used in MIC tests were confirmed to have the density ranging from  $4.8 \times 10^5$   
186 to  $5.3 \times 10^5$  CFU mL<sup>-1</sup> by colony counts.

187 *F. psychrophilum* type strain NCIMB 1947<sup>T</sup> was included in all disc diffusion tests  
188 and the inhibition zone data of this strain were 56 – 72 mm for AMOX<sub>10</sub>, 60 – 75 mm for  
189 ENRO<sub>5</sub>, 57 – 64 mm for FFN<sub>30</sub>, 64 – 86 mm for OTC<sub>30</sub>, 45 – 56 mm for OXO<sub>2</sub> and 16 –  
190 44 mm for SXT<sub>25</sub>. The mean of the ranges of these zone sizes for these six agents against  
191 the *F. psychrophilum* type strain was  $16.5 \pm 7.6$  mm.

192

### 193 **NRI analysis of susceptibility data**

194 The distribution of MIC values of 133 *F. psychrophilum* isolates for ten antimicrobial  
195 agents is shown in Table 3 and 4. MIC-based CO<sub>WT</sub> values of antimicrobial agents are  
196 presented in Table 5. The distribution of disc diffusion zones of the isolates for six  
197 antimicrobials is presented in Figure 1 and the zone data-based CO<sub>WT</sub> values of  
198 antimicrobial agents are shown in Table 6.

199

#### 200 *Oxytetracycline*

201 MIC data for OTC showed a clear bimodal distribution (Table 3). The modal group with  
202 lower MICs was assumed to represent the WT group. NRI analysis calculated the  
203 standard deviation of the log<sub>2</sub> normalised WT distribution as 0.68 and a CO<sub>WT</sub> value of  
204  $\leq 0.25$  mg L<sup>-1</sup> (Table 5). Applying this cut-off, fifty-six (42%) of the 133 isolates analysed  
205 were categorised as WT.

206 The disc diffusion zone sizes for OTC<sub>30</sub> showed considerable diversity at the high  
207 zone end (Figure 1A). However, NRI analysis of these data identified a high zone modal  
208 group with a standard deviation of 7.44 mm. If this modal group was assumed to

209 represent zones obtained from WT isolates, a provisional  $CO_{WT}$  value of  $\geq 51$  mm could  
210 be calculated (Table 6). Applying this cut-off, sixty-five (49%) of the 133 isolates  
211 analysed were categorised as WT.

212 The categorisation of isolates resulting from applying the cut-off of  $\leq 0.25$  mg L<sup>-1</sup> to  
213 the MIC data agreed with the categorisation resulting from applying the disc zone cut-off  
214 of  $\geq 51$  mm to the zone data for 93% of the 133 isolates studied (Figure 2A).

215

### 216 *Amoxicillin and ampicillin*

217 For AMOX, 98 observations (100% of the lower MIC modal observations) and for AMP,  
218 24 observations (24% of the lower MIC modal observations) were recorded as “below-  
219 scale” (Table 3). On this basis, neither of these data sets was considered suitable for NRI  
220 analysis.

221 As in MIC data set for AMP there was a clear separation of the low MIC and high  
222 MIC modal groups, this data set was considered suitable for estimating  $CO_{WT}$  by visual  
223 examination. The estimated value generated by this subjective method was  $\leq 0.125$  mg L<sup>-1</sup>  
224 for AMP. A scatterplot of the paired MIC data for these two beta-lactam agents (Figure  
225 3A) suggested a high correlation between them and also demonstrated that AMOX might  
226 have the same distribution as AMP.

227 The disc diffusion zone sizes for AMOX<sub>10</sub> were also bimodal (Figure 1B). NRI  
228 analysis of these data calculated a standard deviation of the normalised WT distribution  
229 of 5.2 mm and a  $CO_{WT}$  value of  $\geq 56$  mm (Table 6). A scatterplot of the paired MIC

230 values versus inhibition zone sizes for amoxicillin suggested a high correlation between  
231 them (Figure 2B).

232

### 233 *Florfenicol*

234 MIC data for FFN showed a clear unimodal distribution (Table 3). This modal group was  
235 assumed to represent the WT isolates. NRI analysis calculated a standard deviation of the  
236  $\log_2$  normalised WT distribution of 0.68 and a  $CO_{WT}$  value of  $\leq 2$  mg L<sup>-1</sup> (Table 5).

237 The disc diffusion zone sizes for FFN<sub>30</sub> were also unimodal (Figure 1C). NRI  
238 analysis of these data calculated a standard deviation of the normalised WT distribution  
239 of 5.6 mm and a  $CO_{WT}$  value of  $\geq 45$  mm (Table 6).

240 Applying the cut-off of  $\leq 2$  mg L<sup>-1</sup> to the MIC data and the disc zone cut-off of  $\geq 41$   
241 mm to the zone data categorised 100% of the 133 isolates studied as WT (Figure 2C).

242

### 243 *Oxolinic acid, Flumequine and Enrofloxacin*

244 The MIC values of OXO, FLUQ and ENRO were bimodally distributed (Table 3). NRI  
245 analysis calculated the standard deviation of the  $\log_2$  normalised WT distribution as 0.67,  
246 0.57 and 0.74 for OXO, FLUQ and ENRO respectively. The MIC  $CO_{WT}$  values  
247 calculated from these data were  $\leq 0.25$  mg L<sup>-1</sup> for OXO,  $\leq 0.125$  mg L<sup>-1</sup> for FLUQ and  
248  $\leq 0.032$  mg L<sup>-1</sup> for ENRO (Table 5). When these  $CO_{WT}$  values were applied, 21 (16%), 20  
249 (15%) and 20 (15%) of the 133 isolates were categorised as WT with respect to OXO,  
250 FLUQ and ENRO respectively.

251 Scatterplots of the MIC data for OXO against those for FLUQ and ENRO (Figure  
252 3B and 3C) demonstrated a high (>97.7%) categorical agreement in both cases. This  
253 suggests that it would be safe to accept MIC data for OXO as a predictor of reduced  
254 susceptibility to the FLUQ and ENRO (Smith *et al.* 2016). Adoption of this proposal  
255 would reduce the cost of routine susceptibility testing.

256 The disc diffusion zone sizes for OXO<sub>2</sub> were bimodal (Figure 1D). NRI analysis of  
257 these data calculated a standard deviation of the normalised WT distribution of 8.5 mm.  
258 This high standard deviation is probably a result of the fact that high zone modal group  
259 was diverse and composed of only a few observations. This suggests that the disc CO<sub>WT</sub>  
260 value calculated by NRI analysis of  $\geq 30$  mm (Table 6) should only be treated as a  
261 provisional value. Applying the cut-off of  $\leq 0.25$  mg L<sup>-1</sup> to the MIC data for OXO and the  
262 disc zone cut-off of  $\geq 30$  mm to the zone data resulted in 99% agreement in the  
263 categorisation of the 133 isolates studied (Figure 2D).

264 The disc diffusion zone sizes for FLUQ were not determined and those for ENRO  
265 did not show any visually obvious high zone modal group and were not subject to NRI  
266 analysis (Figure 1E).

267

### 268 *Erythromycin*

269 MIC values of ERY had a unimodal distribution. NRI analysis calculated a standard  
270 deviation of the log<sub>2</sub> normalised WT distribution of 0.98 and the CO<sub>WT</sub> value was  
271 calculated as  $\leq 8$  mg L<sup>-1</sup> (Table 3 and 5). This value determined that all 133 *F.*  
272 *psychrophilum* isolates analysed were WT for ERY.

273

274 *Ormetoprim/Sulphadimethoxine and Trimethoprim/Sulphamethoxazole*

275 The distributions of the MIC values for these two potentiated sulfonamide agents were  
276 diverse but appeared to be unimodal (Table 3). NRI analysis generated provisional CO<sub>WT</sub>  
277 values for PRI and SXT of  $\leq 320$  mg L<sup>-1</sup> and  $\leq 160$  mg L<sup>-1</sup>, respectively. However, the  
278 standard deviations calculated for the normalized distribution of these putative WT  
279 observations,  $1.39 \log_2$  mg L<sup>-1</sup> and  $1.67 \log_2$  mg L<sup>-1</sup> for PRI and SXT respectively, were  
280 higher than those recorded for all other agents in this work (Table 5). Therefore, the  
281 validity of these CO<sub>WT</sub> values was questionable.

282 The disc diffusion zone sizes for SXT did not show any visually obvious high zone  
283 modal group and were not subject to NRI analysis (Figure 1F).

284

## 285 **Discussion**

### 286 **Data precision**

#### 287 *Precision of MIC data sets*

288 The precision of any CO<sub>WT</sub> value is a function of the precision of the observational data  
289 used to calculate it. Smith *et al.* (2012) demonstrated that the standard deviations of the  
290 normalised distributions of the log<sub>2</sub> WT observation calculated by the NRI analysis could  
291 provide a proxy measurement of precision. The median of the standard deviation  
292 calculated for 22 *F. psychrophilum* data sets published by Michel *et al.* (2003), Smith *et*  
293 *al.* (2016) and Van Vliet *et al.* (2017) was  $0.70 \log_2$  mg L<sup>-1</sup>. In this work, the median  
294 value of standard deviations calculated for ENRO, ERY, FFN, FLUQ, OTC and OXO

295 (Table 5) was  $0.72 \log_2 \text{ mg L}^{-1}$ . This suggests that the MIC data sets obtained in this work  
296 for these agents were of an acceptable level of precision and were of sufficient quality  
297 that they could be used to calculate  $\text{CO}_{\text{WT}}$  values.

298 The standard deviations calculated for potentiated sulphonamide MIC data,  $1.39$   
299  $\log_2 \text{ mg L}^{-1}$  and  $1.61 \log_2 \text{ mg L}^{-1}$  for PRI and SXT respectively in this work, were,  
300 however, considerably larger and were taken to indicate significant imprecision. Smith *et*  
301 *al.* (2016) and Van Vliet *et al.* (2017), who used the same testing protocol as was used in  
302 this work also reported very low precision in the MIC data they obtained for these agents  
303 (mean  $1.43 \log_2 \text{ mg L}^{-1}$ ). Due to their low precision, it was considered that valid  $\text{CO}_{\text{WT}}$   
304 could not be established for PRI and SXT data obtained in this work.

305

#### 306 *Precision of disc diffusion data sets*

307 Smith & Kronvall (2015) analysed zone data for reference control strains *E. coli* ATCC  
308 25922 and *Aeromonas salmonicida* ATCC 33658 and demonstrated a reduction in  
309 precision as the incubation temperature decreased and time increased. Analysis of the  
310 data obtained from the reference strain *F. psychrophilum* NCIMB 1947<sup>T</sup> and from the test  
311 isolates in this work suggest a similar effect of temperature and time on precision of zone  
312 size data.

313 The mean of the ranges of zone sizes for the control reference strain *E. coli* NCIMB  
314 12210 provided in the guideline VET03-A (CLSI 2006) for tests performed at  $35^\circ\text{C}$ ,  
315  $28^\circ\text{C}$  and  $22^\circ\text{C}$  were  $7.7 \pm 0.8 \text{ mm}$ ,  $8.0 \pm 1.5 \text{ mm}$  and  $11.8 \pm 2.0 \text{ mm}$  respectively (Smith

316 and Kronvall 2015). In this work, the mean range obtained at 15°C for six agents against  
317 the control strain *F. psychrophilum* NCIMB 1947<sup>T</sup> was 16.5 mm ± 7.6 mm

318 The mean of standard deviations of the 19 zone data sets obtained at 28°C in studies  
319 of *Edwardsiella tarda* and *Vibrio harveyi* was 2.53 mm (Lim *et al.* 2016). For 13 data  
320 sets of *A. salmonicida* obtained at 22°C, the mean was 3.9 mm (Miller & Reimschuessel  
321 2006; Smith *et al.* 2007). In this work, the disc diffusion assays were performed at 15°C  
322 and the mean standard deviation of the normalised distributions of the four disc data sets  
323 was 6.7 mm.

324 These comparisons suggest that the low precision of the zone data sets obtained in  
325 this work was most probably a function of the inherent property of this type of assay  
326 rather than any laboratory specific errors in the performance of the assays. However, the  
327 low level of precision suggests that any CO<sub>WT</sub> calculated from these zone data should be  
328 treated as only provisional estimates.

329

### 330 **Categorical agreements**

331 With the calculated MIC CO<sub>WT</sub> and provisional disc diffusion-based CO<sub>WT</sub> of FFN, OXO  
332 and OTC, it is possible to calculate the percentage agreement between the categorisation  
333 of the 133 isolates obtained by analysing the observed MIC measures and the zone size  
334 data. The values of these categorical agreements were 100% for FFN, 99% for OXO and  
335 93% for OTC. This high level of categorical agreement raise the possibility that, although  
336 the disc diffusion protocol used in this work generated data of low precision, the

337 provisional CO<sub>WT</sub> calculated from them may have some value in detecting isolates of  
338 reduced susceptibility.

339 It should, however be noted that Smith & Kronvall (2015) demonstrated that  
340 reduced temperatures and prolonged incubation time increased not only the level of intra-  
341 laboratory variation but also the level of inter-laboratory variation in the data generated.  
342 High inter-laboratory variation of the data will have the consequence that although any  
343 provisional disc CO<sub>WT</sub> calculated in one laboratory may have some value in interpreting  
344 zone data produced in that laboratory, it may be misleading if applied to zone data  
345 obtained in another laboratory. In other words, the CO<sub>WT</sub> values for MIC data calculated  
346 in this work are probably laboratory-independent and of general or ‘universal’  
347 applicability. However, it is probably safer to treat the CO<sub>WT</sub> values for inhibition zone  
348 data generated in this work as only of local applicability. As a consequence, each  
349 laboratory using this protocol to perform disc diffusion assays would have to generate  
350 their own CO<sub>WT</sub> values. The disc diffusion test protocol used in this work has not been  
351 accepted as a standard by CLSI. It is possible that further optimisation such as using a  
352 higher incubation temperature (18°C) may lead to a protocol with increased precision.

353

354 **Comparison of CO<sub>WT</sub> values calculated for MIC measures determined by**  
355 **standardised broth microdilution protocols of CLSI for *F. psychrophilum***

356 The values for any CO<sub>WT</sub> are protocol-specific. It is, therefore, legitimate to compare the  
357 CO<sub>WT</sub> calculated in this work with those published by Smith *et al.* (2016) and Van Vliet  
358 *et al.* (2017), who also used the standardised broth microdilution protocol (CLSI 2014a)

359 and NRI method to calculate CO<sub>WT</sub> for *F. psychrophilum* from MIC data. This  
360 comparison can be made with respect to three agents (FFN, OXO and OTC). For FFN  
361 and OXO, the same CO<sub>WT</sub> values ( $\leq 2$  mg L<sup>-1</sup> and 0.25 mg L<sup>-1</sup> respectively) were  
362 calculated from all three studies. For OTC, Smith *et al.* (2016) and Van Vliet *et al.* (2017)  
363 calculated a CO<sub>WT</sub> of  $\leq 0.125$  mg L<sup>-1</sup> compared to the 0.25 mg L<sup>-1</sup> calculated in this work.  
364 It should, however, be noted that in this work, no isolates were recorded as manifesting  
365 an MIC of 0.25 mg L<sup>-1</sup> for OTC (Table 3) and the categorisation of the 133 isolates  
366 studied here would be the same if either CO<sub>WT</sub> value was applied to them. This  
367 agreement in the CO<sub>WT</sub> values calculated illustrates the value of the use of standardised  
368 test protocols and statistically based interpretive criteria and suggests that it should be  
369 possible for CLSI to set internationally applicable, laboratory-independent ECVs for this  
370 species.

371

### 372 **Frequencies of UK *F. psychrophilum* isolates with reduced susceptibility**

373 Applying the CO<sub>WT</sub> values calculated or, in the case of AMP, estimated in this work  
374 (Table 5) to the MIC data from these 118 UK *F. psychrophilum* isolates, the frequencies  
375 of those with reduced susceptibility were 92% for FLUQ, 90% for ENRO, 88% for OXO,  
376 58% for OTC, 32% for AMP and no isolates were recorded with reduced susceptibility  
377 for FFN and ERY. However, as noted by Smith *et al.* (2016), ERY, a drug whose primary  
378 value is in treating infections by gram-positive bacteria, has never been recommended for  
379 the control of *F. psychrophilum* infections of aquatic animal. There have been two earlier  
380 studies of NWT frequencies in UK *F. psychrophilum* isolates. Rangdale *et al.* (1997)

381 investigated the susceptibility of 47 *F. psychrophilum* isolates, 36 of which were  
382 collected in the UK. However, their MIC data sets were of very low precision (mean log<sub>2</sub>  
383 standard deviation for FFN, OTC and OXO of 3.24 log<sub>2</sub> mg L<sup>-1</sup>) and therefore, reliable  
384 estimates of NWT frequencies could not be assessed. In a smaller study (27 UK *F.*  
385 *psychrophilum* isolates) that used the same testing protocol and statistically based  
386 interpretive criteria as used in this work, Smith *et al.* (2016) reported NWT frequencies  
387 similar to those reported here. When the isolates studied here are combined those studied  
388 by Smith *et al.* (2016), the frequency of NWT phenotypes in the 145 UK isolates  
389 obtained during 2005 – 2015 were 85%, 59% for OXO and OTC respectively, and no  
390 NWT phenotypes were reported for FFN.

391

### 392 **Antibiotic use in UK rainbow trout farming**

393 Verner-Jeffreys & Taylor (2015) reported the use of four agents (FFN, OXY, AMOX and  
394 OXO) in attempts to control RTFS in the UK. The survey revealed that FFN was the  
395 treatment of choice in the industry. These FFN treatments were generally considered very  
396 effective. Where other antimicrobials (OTC, OXO or AMOX) were used, the therapeutic  
397 response was reported as either mixed or poor.

398       These anecdotal reports of comparative treatment efficacies reflect closely the  
399 frequencies with which isolates of reduced susceptibility were detected in this work. This  
400 in turn suggests that routine susceptibility testing, associated with appropriate  
401 interpretation of these data obtained, would be cost-effective and an essential element in  
402 the prudent use of antibiotics in aquaculture.

403 Verner-Jeffreys & Taylor (2015) reported that within the UK most batches of  
404 rainbow trout were treated with FFN at least once during every production cycle. Thus,  
405 given the relatively high frequency of NWT phenotypes detected with respect to the  
406 alternative agents available (OXO, OTC and AMOX), it would appear that, as it currently  
407 operates, the UK rainbow trout industry is critically dependent on the continued clinical  
408 efficacy of FFN. Some concern must be expressed about the long-term sustainability of  
409 an industry that would be affected by the emergence of strains of *F. psychrophilum* that  
410 were clinically resistant to this agent.

411 As FFN is the agent of choice to treat *F. psychrophilum* infection in many countries,  
412 it is reasonable to postulate that this critical dependence of the continued clinical efficacy  
413 of FFN is not unique to the UK but is wide-spread in the global trout farming industry.  
414 The global situation with respect to FFN susceptibility of *F. psychrophilum* can be  
415 assessed from a number of studies that have been published. Studies that have employed  
416 standard MIC testing protocols and that generated data of adequate precision have been  
417 reported from Denmark and the UK (Smith *et al.* 2016), Chile (Miranda *et al.* 2016) and  
418 USA (Van Vliet *et al.* 2017). Studies of the antimicrobial susceptibility of Danish (Bruun  
419 *et al.* 2000) and French (Michel *et al.* 2003) *F. psychrophilum* isolates that used non-  
420 standardised agar dilution protocols have also been published Combining the data  
421 presented in these studies with the data generated in this study provides a total of 829  
422 measurements of FFN susceptibility, of which only two (0.2%), both collected in Chile,  
423 were categorised as NWT with respect to FFN. Recently the presence of a region  
424 containing resistance genes to florfenicol (*floR*), tetracycline (*tetX*), streptothricin and

425 chloramphenicol acetyltransferase gene was detected in *Chryseobacterium* spp. from  
426 rainbow trout (Verner-Jeffreys *et al.* 2017). However, this resistance gene cassette was  
427 not widely distributed in Flavobacteriaceae isolates (Verner-Jeffreys *et al.* 2017).

428         These data would indicate, rather surprisingly, that the selective pressure that must  
429 have resulted from the use of this agent during the 25 or more years since the introduction  
430 of the antibiotic to aquaculture (Smith 2008) has not yet resulted in any significant  
431 emergence of strains of *F. psychrophilum* strains with reduced susceptibility to this agent.  
432 However, it cannot be automatically assumed that this situation will continue. Given the  
433 significance of FFN to the global trout farming industry, and as recommended by the  
434 World Animal Health Organisations ([http://www.oie.int/international-standard-](http://www.oie.int/international-standard-setting/aquatic-code/access-online)  
435 [setting/aquatic-code/access-online](http://www.oie.int/international-standard-setting/aquatic-code/access-online)), it is essential that programmes designed to detect any  
436 emergence of isolates of *F. psychrophilum* with reduced susceptibility to this agent are  
437 implemented as a matter of urgency by all relevant authorities.

438

## 439 **Conclusions**

440 Interpretation of MIC data by NRI analysis for *F. psychrophilum* generated by the  
441 standardised microdilution protocol (CLSI 2014a) provided an overview of the  
442 frequencies of isolates manifesting reduced susceptibility in 118 UK isolates. There was a  
443 general agreement between the frequencies of isolates manifesting WT phenotypes for  
444 the agents FFN, OXO and OTC, observed in this work, and the reports of their clinical  
445 success when used in commercial farms in the UK. On the basis of this, it is strongly  
446 recommended that, in order to ensure rational and prudent use of antibiotics to control *F.*

447 *psychrophilum* infections, susceptibility testing using standardised methods should be  
448 performed in association with all on-farm administrations of the antibiotics.

449 The Aquatic Animal Health Code of the World Animal Health Organisation  
450 recommends that all relevant authorities should implement programmes for the  
451 monitoring and surveillance of the susceptibility of aquatic animal pathogens to  
452 antibiotics used in their areas. As the UK trout farming industry is critically dependent on  
453 the continued efficacy of FFN in the control of RTFS, the implementation of such a  
454 programme with respect to *F. psychrophilum* would appear to be a priority for the UK.  
455 The standardised MIC susceptibility testing protocol of CLSI and the epidemiological  
456 cut-off values developed in this work would provide the analytical methods for such a  
457 programme.

458

#### 459 **Acknowledgements**

460 This work was supported by the EU project TARGETFISH, Targeted Disease  
461 Prophylaxis in European Fish Farming, under FP7 (grant no. 311993). Special thanks are  
462 expressed to Dr Robin Wardle from MSD Animal Health for generously donating  
463 Sensititre CMP1MSP plates; Mr Richard Hopewell from Dawnfresh Farming, Dr Tim  
464 Wallis from Ridgeway Biologicals, Dr Matthijs Metselaar from Fish Vet Group and Dr  
465 Margaret Crumlsh from the Bacteriology laboratory, University of Stirling for providing  
466 clinical *F. psychrophilum* strains.

467

#### 468 **References**

469 Baquero F. (1990) Resistance to quinolones in gram-negative microorganisms:  
470 mechanism and prevention. *European Urology* **17**, 3-12.

471 Barnes M.E. & Brown M.L. (2011) A review of *Flavobacterium psychrophilum* biology,  
472 clinical signs, and bacterial cold water disease prevention and treatment. *The Open Fish*  
473 *Science Journal* **4**, 40-48.

474 Bauer A.U., Kirby W.M., Sherris J.C. & Track M (1966) Antibiotic susceptibility testing  
475 by a standardized single disc method. *Journal of Clinical Pathology* **45**, 493–494.

476 Borg A.F. (1948) Studies on myxobacteria associated with diseases in salmonid fishes.  
477 Ph.D. Thesis. University of Washington. Seattle.

478 Boutin S., Bernatchez L., Audet C. & Derôme N. (2012) Antagonistic effect of  
479 indigenous skin bacteria of brook charr (*Salvelinus fontinalis*) against *Flavobacterium*  
480 *columnare* and *F. psychrophilum*. *Veterinary Microbiology* **155**, 355-361.

481 Boyacıoğlu M. & Akar F. (2012) Isolation of *Flavobacterium psychrophilum* causing  
482 rainbow trout fry syndrome and determination of an effective antibacterial treatment in  
483 rainbow trout (*Oncorhynchus mykiss*) fry. *Kafkas Üniversitesi Veteriner Fakültesi*  
484 *Dergisi* **18**, 197-203.

485 Boyacıoğlu M, Kum C., Kirkan S., Sekkin S., Parin U., Karademir U. & Akar F. (2015)  
486 Comparison of *in vitro* and *in vivo* antibacterial efficacy for the control of  
487 *Flavobacterium psychrophilum* in rainbow trout (*Oncorhynchus mykiss*) fry: the first  
488 genotypical evidence in West Aegean region of Turkey. *Turkish Journal of Veterinary*  
489 *and Animal Sciences* **39**, 314-321.

490 Bruun M.S., Schmidt A.S., Madsen L. & Dalsgaard I. (2000) Antimicrobial resistance  
491 patterns in Danish isolates of *Flavobacterium psychrophilum*. *Aquaculture* **187**, 201-212.

492 Bruun M.S., Madsen L. & Dalsgaard I. (2003) Efficiency of oxytetracycline treatment in  
493 rainbow trout experimentally infected with *Flavobacterium psychrophilum* strains having  
494 different in vitro antibiotic susceptibilities. *Aquaculture* **215**, 11-20.

495 Burbank D., LaPatra S., Fornshell G. & Cain K. (2012) Isolation of bacterial probiotic  
496 candidates from the gastrointestinal tract of rainbow trout, *Oncorhynchus mykiss*  
497 (Walbaum), and screening for inhibitory activity against *Flavobacterium*  
498 *psychrophilum*. *Journal of Fish Diseases* **35**, 809-816.

499 Castillo D., Higuera G., Villa M., Middelboe M., Dalsgaard I., Madsen L. & Espejo R.  
500 (2012) Diversity of *Flavobacterium psychrophilum* and the potential use of its phages for  
501 protection against bacterial cold water disease in salmonids. *Journal of Fish Diseases* **35**,  
502 193-201.

503 Cepeda C. & Santos Y. (2000) Rapid and low-level toxic PCR-based method for routine  
504 identification of *Flavobacterium psychrophilum*. *International Microbiology* **3**, 235-238.

505 CLSI (2006) *Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated*  
506 *from Aquatic Animals*, Approved Guideline VET03-A. Clinical and Laboratory Standards  
507 Institute, Wayne, PA.

508 CLSI (2008) *Development of In-Vitro Susceptibility Testing Criteria and Quality Control*  
509 *Parameters for Veterinary Antimicrobial Agents: Approved Guideline – third edition*,  
510 CLSI document M37-A3. Clinical and Laboratory Standards Institute, Wayne, PA.

511 CLSI (2014a) *Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated from*  
512 *Aquatic Animals, Approved Guideline VET04-A2*. Clinical and Laboratory Standards  
513 Institute, Wayne, PA.

514 CLSI (2014b) *Performance Standards for Antimicrobial Susceptibility Testing of*  
515 *Bacteria Isolated from Aquatic Animals; Second Informational Supplement*. CLSI  
516 document VET03/04-S2. Clinical and Laboratory Standards Institute, Wayne, PA.

517 Dalsgaard I. & Madsen L. (2000) Bacterial pathogens in rainbow trout, *Oncorhynchus*  
518 *mykiss* (Walbaum), reared at Danish freshwater farms. *Journal of Fish Diseases* **23**, 199-  
519 209.

520 Del Cerro A., Márquez I. & Prieto J.M. (2010) Genetic diversity and antimicrobial  
521 resistance of *Flavobacterium psychrophilum* isolated from cultured rainbow trout,  
522 *Oncorhynchus mykiss* (Walbaum), in Spain. *Journal of Fish Diseases* **33**, 285-291.

523 Durmaz Y., Onuk E.E. & Çiftci A. (2012) Investigation of the presence and antibiotic  
524 susceptibilities of *Flavobacterium psychrophilum* in rainbow trout farms (*Oncorhynchus*  
525 *mykiss* Walbaum, 1792) in The Middle and Eastern Black Sea Regions of Turkey.  
526 *Ankara Üniversitesi Veteriner Fakültesi Dergisi* **59**, 141-146.

527 Gao P., Mao D., Luo Y., Wang L., Xu B. & Xu L. (2012) Occurrence of sulphonamide  
528 and tetracycline-resistant bacteria and resistance genes in aquaculture environment.  
529 *Water Research* **46**, 2355-2364.

530 Gómez E., Méndez J., Cascales D. & Guijarro J.A. (2014) *Flavobacterium*  
531 *psychrophilum* vaccine development: a difficult task. *Microbial Biotechnology* **7**, 414-  
532 423.

533 Grape M., Farra A., Kronvall G. & Sundström L. (2005) Integrons and gene cassettes in  
534 clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. *Clinical*  
535 *Microbiology and Infection* **11**, 185-192

536 Henríquez-Núñez H., Evrard O., Kronvall G. & Avendaño-Herrera R. (2012)  
537 Antimicrobial susceptibility and plasmid profiles of *Flavobacterium psychrophilum*  
538 strains isolated in Chile. *Aquaculture* **354-355**, 38-44.

539 Hesami S. & Parkman J. (2010) Antimicrobial susceptibility of *Flavobacterium*  
540 *psychrophilum* isolates from Ontario. *Journal of Aquatic Animal Health* **22**, 39-49.

541 Izumi S. & Aranishi F. (2004) Relationship between *gyrA* mutations and quinolone  
542 resistance in *Flavobacterium psychrophilum* isolates. *Applied and Environmental*  
543 *Microbiology* **70**, 3968-3972.

544 Kim J.H., Gomez D.K., Nakai T. & Park S.C. (2010a) Isolation and identification of  
545 bacteriophages infecting ayu *Plecoglossus altivelis altivelis* specific *Flavobacterium*  
546 *psychrophilum*. *Veterinary Microbiology* **140**, 109-115.

547 Korkea-aho T., Heikkinen J., Thompson K., von Wright A. & Austin B. (2011)  
548 *Pseudomonas* sp. M174 inhibits the fish pathogen *Flavobacterium psychrophilum*.  
549 *Journal of Applied Microbiology* **111**, 266-277.

550 Kronvall G. (2003) Determination of the real standard distribution of susceptible strains  
551 in zone histograms. *International Journal of Antimicrobial Agents* **22**, 7-13.

552 Kronvall G., Kahlmeter G., Myhre E. & Galas M.F. (2003) A new method for normalized  
553 interpretation of antimicrobial resistance from disk test results for comparative purposes.  
554 *Clinical Microbiology and Infection* **9**, 120-132.

555 Kronvall G. (2010) Normalized resistance interpretation as a tool for establishing  
556 epidemiological MIC susceptibility breakpoints. *Journal of Clinical Microbiology* **48**,  
557 4445-4452.

558 Kronvall G. & Smith P. (2016). Normalized resistance interpretation, the NRI method.  
559 Review of NRI disc test applications and guide to calculations. *ACTA Pathologica*,  
560 *Microbiologica et immunologica Scandinavica* **124**, 1023-1030.

561 Kum C., Kirkan S., Sekkin S., Akar F. & Boyacioglu M. (2008) Comparison of *in vitro*  
562 antimicrobial susceptibility in *Flavobacterium psychrophilum* isolated from rainbow trout  
563 fry. *Journal of Aquatic Animal Health* **20**, 245-251.

564 Lim Y-J., Kim D-H., Roh H.J., Park M-A., Park C-I. & Smith P. (2016) Epidemiological  
565 cut-off values for disc diffusion data generated by standard test protocols from  
566 *Edwardsiella tarda* and *Vibrio harveyi*. *Aquaculture International*. DOI 10.1007/s10499-  
567 016-9977-0

568 Lorenzen E., Dalsgaards I. & Bernardet J-F. (1997) Characterization of isolates of  
569 *Flavobacterium psychrophilum* associated with coldwater disease or rainbow trout fry  
570 syndrome I: phenotypic and genomic studies. *Diseases of Aquatic Organisms* **31**, 197-  
571 208.

572 Michel C., Kerouault B. & Martin C. (2003) Chloramphenicol and florfenicol  
573 susceptibility of fish-pathogenic bacteria isolated in France: comparison of minimum  
574 inhibitory concentration, using recommended provisory standards for fish bacteria.  
575 *Journal of Applied Microbiology* **95**, 1008-1015.

576 Miller R.A. & Reimschuessel R. (2006) Epidemiologic cutoff values for antimicrobial  
577 agents against *Aeromonas salmonicida* isolates determined by frequency distributions of  
578 minimal inhibitory concentration and diameter of zone of inhibition data. *American*  
579 *Journal of Veterinary Research* **67**, 1837-1843.

580 Minoque E., Barry T. Carroll C. & Smith P. (2013) Setting epidemiological cut-off  
581 values for *Aeromonas salmonicida* disc diffusion data capable of discriminating between  
582 strains on the basis of their possession of *sulI* genes. *Aquaculture* **364-365**, 329-332.

583 Miranda C.D, Smith P., Rojas R., Contreras-Lynch S. & Alonso Vega J.M. (2016)  
584 Antimicrobial susceptibility of *Flavobacterium psychrophilum* from Chilean salmon  
585 farms and their epidemiological cut-off values using agar dilution and disk diffusion  
586 methods. *Frontiers in Microbiology*. Doi: 10.3389/fmicb.2016.01880.

587 Ngo T.P.H., Bartie K.L., Thompson K.D., Verner-Jeffreys D.W., Hoare R. & Adams A.  
588 (2017) Genetic and serological diversity of *Flavobacterium psychrophilum* isolates from  
589 salmonids in United Kingdom. *Veterinary Microbiology*. Doi:  
590 10.1016/j.vetmic.2017.01.032

591 Nilsen H., Johansen R., Colquhoun D.J., Kaada I., Bottolfsen K., Vågnes Ø. & Olsen A.  
592 B. (2011) *Flavobacterium psychrophilum* associated with septicaemia and necrotic  
593 myositis in Atlantic salmon *Salmo salar*: a case report. *Diseases of Aquatic Organisms*  
594 **97**, 37-46.

595 Pacha R.E. (1968) Characteristics of *Cytophaga psychrophila* (Borg) isolated during  
596 outbreaks of bacterial cold-water disease. *Applied Microbiology* **16**, 97-101.

597 Prescott J. F. (2007) Sulfonamides, diaminopyrimidines, and their combinations. In:  
598 Antimicrobial Therapy in Veterinary Medicine 4<sup>th</sup> edition, Wiley-Blackwell, pp. 249-262

599 Rangdale R.E., Richards R.H. & Alderman D.J. (1997) Minimum inhibitory  
600 concentrations of selected antimicrobial compounds against *Flavobacterium*  
601 *psychrophilum* the causal agent of rainbow trout fry syndrome (RTFS). *Aquaculture* **158**,  
602 193-201.

603 Romero J., Feijoó C. G. & Navarrete P. (2012) Antibiotics in aquaculture – use, abuse  
604 and alternatives. In Health and Environment in Aquaculture, InTech, 159-198.

605 Schmidt A.S., Bruun M.S., Dalsgaard I., Pedersen K. & Larsen J.L. (2000) Occurrence of  
606 antimicrobial resistance in fish-pathogenic and environmental bacteria associated with  
607 four Danish rainbow trout farms. *Applied and Environmental Microbiology* **66**, 4908-  
608 4915.

609 Silley P. (2012) Susceptibility testing methods, resistance and breakpoints: what do these  
610 terms really mean? *Scientific and Technical Review of the Office International des*  
611 *Epizooties* **31**, 33-41.

612 Smith, P. (2008). “Antimicrobial resistance in aquaculture” in *Changing Trends in*  
613 *Managing Aquatic Animal Disease Emergencies*, ed. E.-M. Bernoth (Paris: OIE), **27**,  
614 243–264.

615 Smith P. & Kronvall G. (2014) Estimating the precision of disc diffusion antibiotic  
616 susceptibility data published by the European Committee on Antimicrobial Susceptibility  
617 Testing. *APMIS* DOI: 10.1111/am.12262 (in press).

618 Smith P. & Kronvall G. (2015) Effect of incubation temperature and time on the  
619 precision of data generated by antibiotic disc diffusion assays. *Journal of Fish Diseases*  
620 **38**, 629-536.

621 Smith P, Ruane N.M., Douglas I., Carroll C., Kronvall G. & Flemming G.T.A. (2007)  
622 Impact of inter-lab variation on the estimation of epidemiological cut-off values for disc  
623 diffusion susceptibility test data for *Aeromonas salmonicida*. *Aquaculture* **272**, 168-179.

624 Smith P., Schwarz T. & Verner-Jeffreys DW. (2012). Use of normalised resistance  
625 analyses to set interpretive criteria for antibiotic disc diffusion data produce by  
626 *Aeromonas* spp. *Aquaculture* **326–329**, 27-35.

627 Smith P., Alday-Sanz V., Matysczak J., Moulin G., Lavilla-Pitogo C.R. & Prater D.  
628 (2013) Monitoring and surveillance of antimicrobial resistance in mircoorganisms  
629 associated with aquatic animals. *Scientific and Technical Review* **32**, 583-593.

630 Smith P., Endris R., Kronvall G., Thomas V., Verner-Jeffreys D., Wilhelm C. &  
631 Dalsgaard I. (2016) Epidemiological cut-off values for *Flavobacterium psychrophilum*  
632 MIC data generated by a standard test protocol. *Journal of Fish Diseases* **39**, 143-154.

633 Soltani M., Shanker S. & Munday B.L. (1995) Chemithery of *Cytophaga/Flecibacter-*  
634 like bacteria (CFLB) infections in fish: studies validating clinical efficacies of selected  
635 antimicrobials. *Journal of Fish Diseases* **18**, 555-565.

636 Soule M., Lafrentz S., Cain K., Lapatra S. & Call D.R. (2005) Polymorphisms in 16S  
637 rRNA genes of *Flavobacterium psychrophilum* correlate with elastin hydrolysis and  
638 tetracycline resistance. *Diseases of Aquatic Organisms* **65**, 209-216.

639 Stenholm A.R., Dalsgaard I. & Middelboe M. (2008) Isolation and characterization of  
640 bacteriophages infecting the fish pathogen *Flavobacterium psychrophilum*. *Applied and*  
641 *Environmental Microbiology* **74**, 4070-4078.

642 Ström- Bestor M. & Wiklund T. (2011) Inhibitory activity of *Pseudomonas* sp. on  
643 *Flavobacterium psychrophilum*, *in vitro*. *Journal of Fish Diseases* **34**, 255-264.

644 Sundell K., Heinikainen S. & Wiklund T. (2013) Structure of *Flavobacterium*  
645 *psychrophilum* populations infecting farmed rainbow trout *Oncorhynchus mykiss*.  
646 *Diseases of Aquatic Organisms* **103**, 111-119.

647 Toyama T., Kita-Tsukamoto K. & Wakabayashi H. (1994) Identification of *Cytophaga*  
648 *psychrophila* by PCR targeted 16S ribosomal RNA. *Fish Pathology* **29**, 271-275.

649 Valdebenito S. & Avendaño-Herrera R. (2009) Phenotypic, serological and genetic  
650 characterization of *Flavobacterium psychrophilum* strains isolated from salmonids in  
651 Chile. *Journal of Fish Diseases* **32**, 321-333.

652 Van Vliet D., Loch T.P., Smith P. & Faisal M. (2017) Antimicrobial susceptibilities of  
653 *Flavobacterium psychrophilum* isolates from the Great Lakes Basin, Michigan. *Microbial*  
654 *Drug Resistance*. Doi:10.1089/mdr.2016.0103.

655 Verner-Jeffreys D.W. & Taylor N.J. (2015) Review of freshwater treatments used in the  
656 Scottish freshwater rainbow trout aquaculture industry. *Scottish Aquaculture Research*  
657 *Forum Report SARF100*

658 Verner-Jeffreys, D.W., Brazier, T., Perez, R.Y., Ryder, D., Card, R.M., Welch, T.J.,  
659 Hoare, R., Ngo, T., MacLaren, N., Ellis, R., Bartie, K.L., Feist, S.W., Rowe, W.M.P.,  
660 Adams, A. & Thompson, K.D. (2017) Detection of the florfenicol resistance gene *floR* in

661 *Chryseobacterium* isolates from rainbow trout. Exception to the general rule? *FEMS*

662 *Microbiol Ecol.* Doi: 10.1093/femsec/fix015.

663

664 **Table 1.** Summary of 118 UK *F. psychrophilum* isolates analysed in this study

Location	Host source	No. of sites	Site	Year of isolation	No. of sampling times	No. of strains	No. of genotypes (*)	No. of plasmid profiles (*)
<b>Scotland</b>	<b>RT(93)/ AS(14)</b>	<b>20</b>		<b>2005-2015</b>	<b>46</b>	<b>102</b>	<b>47</b>	<b>7</b>
			Scot I	2005-2014	16	25	11	4
			Scot II	2013	1	1	1	1
			Scot III	2011-2015	4	13	9	4
			Scot IV	2013	1	5	2	2
			Scot V	2013-2015	4	27	16	5
			Scot VI	2009	1	1	1	1
			Scot VII	2007	1	1	1	1
			Scot VIII	2005	1	1	1	1
			Scot IX	2006	1	1	1	1
			Scot X	2011-2013	2	3	2	1
			Scot XI	2015	1	4	3	1
			Scot XII	2010	1	1	1	1
			Scot XIII	2005	1	1	1	1
			Scot XIV	2013	1	2	1	1
			Scot XV	2013	2	3	2	1
			Scot XVI	2014-2015	4	9	4	3
			Scot XVII	2007	1	1	1	1
			Scot XVIII	2009	1	1	1	1
			Unknown (2)	2009-2012	2	2	2	2
<b>England</b>	<b>RT</b>	<b>6</b>		<b>2007-2015</b>	<b>8</b>	<b>13</b>	<b>5</b>	<b>2</b>
			Eng I	2013	3	8	4	2
			Eng II	2015	1	1	1	1
			Eng III	2015	1	1	1	1
			Eng IV	2015	1	1	1	1
			Eng V	2007	1	1	1	1
			Eng VI	2007	1	1	1	1
<b>Northern Ireland</b>	<b>RT</b>	<b>1</b>	<b>N Ire I</b>	<b>2013</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>2</b>
<b>Total</b>	<b>RT(111)/ AS(14)</b>			<b>2005-2015</b>	<b>56</b>	<b>118</b>	<b>51</b>	<b>7</b>

665 RT, rainbow trout; AS, Atlantic salmon

666 (\*) Genotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).

667

668

669 **Table 2.** Fifteen *F. psychrophilum* isolates from outside the UK used in this study  
 670

Countries	Host source	Year of isolation	No. of strains	No. of genotypes <sup>a</sup>	No. of plasmid profiles <sup>a</sup>
Chile	RT	1995-1997	2	2	2
Denmark	RT	1990-1994	3	3	1
Finland	RT	1996	2	2	1
France	RT	unknown-2013	3	2	1
Ireland	AS	2006	1	1	1
USA <sup>b</sup>	RT(3)/CS(1)	unknown - 2004	4	4	2
<b>Total</b>	<b>RT(13)/AS(1)/CS(1)</b>	<b>unknown - 2013</b>	<b>15</b>	<b>13</b>	<b>3</b>

671 RT, rainbow trout; AS, Atlantic salmon; CS, coho salmon

672 <sup>a</sup> Pulsotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).

673 <sup>b</sup> including the *F. psychrophilum* type strain NCIMB 1947<sup>T</sup>

674

675

676 **Table 3.** MIC values (mg L<sup>-1</sup>) determined for 133 *F. psychrophilum* isolates

	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale	
β lactams																	
AMOX	93	Shaded area									19	13	8				
AMP	24	Shaded area					66	3			15	17	8				
Macrolides																	
ERY	4	Shaded area								4	24	93	8				
Phenicols																	
FFN		Shaded area						1	9	69	54						
Quinolones																	
ENRO				7	10	3	3	51	17	14	28	Shaded area					
FLUQ		Shaded area				3	16	1	1	3	41	13	13	Shaded area		42	
OXO		Shaded area					7	13	1	1	6	47	Shaded area			58	
Tetracyclines																	
OTC		Shaded area				12	40	4		2		7	33	32	Shaded area		3
	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale	

677 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.

678 Off scale indicates the number of strains whose MIC lay outside of the range that could be determined using these plates.

679

680

681 **Table 4.** MIC values (mg L<sup>-1</sup>) determined for potentiated sulphonamide drugs against 133 *F. psychrophilum* isolates

682

	Off scale	0.008/0.15	0.015/0.30	0.03/0.59	0.06/1.19	0.12/2.38	0.25/4.75	0.5/9.5	1/19	2/38	4/76	Off scale
PRI						1	2	15	28	43	29	15
SXT					1	11	37	30	48			6

683

684 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.

685 Table 5. Cut-off values (CO<sub>WT</sub>) calculated using NRI from 133 MIC observations

Agent	Number of WT observations	Standard deviation <sup>a</sup> (log <sub>2</sub> mg L <sup>-1</sup> )	CO <sub>WT</sub> (mg L <sup>-1</sup> )
AMP <sup>b</sup>	93 (70%)	ND <sup>c</sup>	≤ 0.125
ENRO	20 (15%)	0.74	≤ 0.032
ERY	133 (100%)	0.98	≤ 8
FFN	133 (100%)	0.68	≤ 2
FLUQ	20 (15%)	0.57	≤ 0.125
OTC	56 (42%)	0.68	≤ 0.25
OXO	21 (16%)	0.67	≤ 0.25
PRI	133 (100%)	1.39	≤ 16/304
SXT	133 (100%)	1.61	≤ 8/152

686 <sup>a</sup> Standard deviation of the normalised distribution of MIC values for WT strains.

687 <sup>b</sup> CO<sub>WT</sub> value of AMP was estimated by visual examination.

688 <sup>c</sup> ND: not determined

689

690

691 Table 6. Provisional cut-off values (CO<sub>WT</sub>) calculated using NRI from 133 inhibition zone  
692 observations

Agent	Number of WT observations	Standard deviation* (mm)	CO <sub>WT</sub> (mm)
AMOX <sub>10</sub>	90 (68%)	5.20	≥ 56
FFN <sub>30</sub>	133 (100%)	5.61	≥ 45
OTC <sub>30</sub>	65 (49%)	7.44	≥ 51
OXO <sub>2</sub>	20 (15%)	8.50	≥ 30

693 \* Standard deviation of the normalised distribution of MIC values for WT strains.





694

695


696

697

698



722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744



**Figure 1.** Distribution of 133 *F. psychrophilum* strains according to inhibition zone diameters generated by disc diffusion method for 30 µg oxytetracycline (A, OTC<sub>30</sub>), 10 µg amoxicillin (B, AMOX<sub>10</sub>), 30 µg florfenicol (C, FFN<sub>30</sub>), 2 µg oxolinic acid (D, OXO<sub>2</sub>), 5 µg enrofloxacin (E, ENRO<sub>5</sub>) and 25 µg trimethoprim/sulphamethoxazole (F, SXT<sub>25</sub>). The continuous line represents the 8 point rolling means, the vertical dashed line represents the calculated disc diffusion-based cut-off value.

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761





762

763

764


765

766



767 **Figure 2.** Plot of 133 paired MIC values versus disc diffusion zone diameters for  
 768 oxytetracycline (A), florfenicol (B) and oxolinic acid (C). A continuous thick line  
 769 presents the calculated cut-off line of the microbial agent.

770



788 **Figure 3.** Plot of 133 paired MIC values between antimicrobial agents within beta-  
 789 lactam group (A: ampicillin and amoxicillin) and quinolone group (B: oxolinic acid  
 790 and flumequine; C: oxolinic acid and enrofloxacin). A continuous thick line presents  
 791 the calculated cut-off line of the microbial agent. A dashed line presents an estimated  
 792 cut-off value.